Dec 15, 2025 • MarketBeat
SOMEWHAT-BEARISH
Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO
Alkeon Capital Management LLC increased its stake in Akero Therapeutics, Inc. by 19.3% in the second quarter, now owning 1,850,934 shares valued at $98.8 million. Despite this, company insiders, including the COO and CEO, sold 55,000 shares worth $2.79 million, reducing insider ownership to 7.07%. Akero Therapeutics has a "Hold" consensus rating with an average target price of $73.38, having recently missed quarterly EPS expectations and faced several analyst downgrades.
Dec 14, 2025 • MarketBeat
SOMEWHAT-BEARISH
Frazier Life Sciences Management L.P. Acquires New Shares in Akero Therapeutics, Inc. $AKRO
Frazier Life Sciences Management L.P. has acquired a new position of 366,784 shares in Akero Therapeutics, valued at approximately $19.57 million, making it their 27th-largest holding. Despite significant institutional investment, company insiders have sold 55,000 shares, and analysts have downgraded the stock to a "Hold" rating with a target price of $73.38, following a reported EPS miss in the last quarter.
Dec 14, 2025 • MarketBeat
NEUTRAL
Hudson Bay Capital Management LP Buys 84,573 Shares of Akero Therapeutics, Inc. $AKRO
Hudson Bay Capital Management LP increased its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 28% in Q2, acquiring an additional 84,573 shares to hold a total of 386,523 shares valued at $20.63 million. This comes despite significant insider selling, with the COO and CEO offloading 42,500 shares totaling approximately $2.2 million over the last 90 days. The stock currently trades at $54.65, with analysts maintaining a "Hold" consensus rating and an average target price of $73.38.
Dec 13, 2025 • MarketBeat
NEUTRAL
General Atlantic L.P. Acquires 500,000 Shares of Akero Therapeutics, Inc. $AKRO
General Atlantic L.P. increased its stake in Akero Therapeutics, Inc. by purchasing an additional 500,000 shares, bringing its total ownership to 5,733,989 shares and making it the firm's fifth-largest holding. Other institutional investors also increased their positions, yet analyst sentiment has cooled with several downgrades to a consensus "Hold" rating. Insiders, notably CEO Andrew Cheng and COO Jonathan Young, have sold a significant number of shares, indicating a mixed outlook for the stock.
Dec 12, 2025 • Barchart.com
SOMEWHAT-BULLISH
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio
The Liver Fibrosis market is projected to reach approximately USD 1,800 million in 2023 and is expected to grow significantly by 2034, driven by increasing prevalence of chronic liver diseases, advancements in diagnostics, and novel drug development. Key pharmaceutical companies like Madrigal Pharmaceuticals and Akero Therapeutics are leading the development of new therapies, with recent approvals and promising clinical trial results for treatments such as Rezdiffra and efruxifermin. DelveInsight's report provides an in-depth analysis of market trends, epidemiology, and emerging therapies across the 7MM (United States, EU4, UK, and Japan).
Dec 11, 2025 • Barchart.com
SOMEWHAT-BULLISH
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio
The liver fibrosis market is projected to grow significantly through 2034, driven by an increasing prevalence of chronic liver diseases, advancements in diagnostics, and ongoing drug development. Key companies including Madrigal Pharmaceuticals and Akero Therapeutics are developing therapies, with REZDIFFRA (resmetirom) projected to reach a market value of around USD 2,500 million in the 7MM by 2034. The US leads in liver fibrosis cases, and new treatments for metabolic dysfunction-associated steatohepatitis (MASH) and advanced liver fibrosis are rapidly progressing through clinical trials.